Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020

Ying Kai Chan; Andrew D Dick; Sara Mary Hall; Thomas Langmann; Curtis L Scribner; Brian C Mansfield; Ocular Gene Therapy Inflammation Working Group

doi:10.1167/tvst.10.4.3

Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020

Transl Vis Sci Technol. 2021 Apr 1;10(4):3. doi: 10.1167/tvst.10.4.3.

Authors

Ying Kai Chan¹, Andrew D Dick^{2

3}, Sara Mary Hall⁴, Thomas Langmann⁵, Curtis L Scribner⁶, Brian C Mansfield⁷; Ocular Gene Therapy Inflammation Working Group

Affiliations

¹ Harvard Medical School, Boston, MA, USA.
² UCL Institute of Ophthalmology, London, UK.
³ University of Bristol, Bristol, UK.
⁴ Hubble Therapeutics, Boston, MA, USA.
⁵ University Hospital, Cologne, Germany.
⁶ Oakland, CA, USA.
⁷ Foundation Fighting Blindness, Columbia, MD, USA.

Abstract

Subclinical or clinical inflammation often arises during ocular gene therapy with viral vectors. Understanding the biological bases and impacts on efficacy are important for clinical management and the improvement of future therapies.

MeSH terms

Blindness / genetics
Genetic Therapy*
Genetic Vectors* / genetics
Humans
Inflammation / genetics
Vision, Ocular